Most resuscitated cardiac arrest patients die in the intensive care unit due to hypoxic brain injury [1]. The pathophysiological process includes disturbed cerebral autoregulation resulting in inadequate blood flow and ischemia, and means to alleviate this could include giving more oxygen or increasing the mean arterial pressure (MAP) with vasopressors [2]. Supplemental oxygen may result in hyperoxia, which has been associated with harmful reactive oxygen species [3]. Whether limiting oxygen use could decrease brain injury after cardiac arrest has received much attention. Pilot studies have shown through biomarker levels that targeting a higher MAP than the recommended 65 mmHg may alleviate brain and cardiac injury [4]. The lack of large randomized controlled trials on MAP and oxygen has been a major shortcoming [5]. In 2022, the BOX and EXACT trials (Table 1) were published, with major ramifications for post-cardiac arrest management.